Table of Content

Executive Summary



Chapter 1 – Introduction



Chapter 2 – Trends in hematology dealmaking



2.1. Introduction

2.2. Hematology partnering over the years

2.3. Hematology partnering by deal type

2.4. Hematology partnering by industry sector

2.5. Hematology partnering by stage of development

2.6. Hematology partnering by technology type

2.7. Hematology partnering by therapeutic indication



Chapter 3 – Financial deal terms for hematology partnering



3.1. Introduction

3.2. Disclosed financials terms for hematology partnering

3.3. Hematology partnering headline values

3.4. Hematology deal upfront payments

3.5. Hematology deal milestone payments

3.6. Hematology royalty rates



Chapter 4 – Leading hematology deals and dealmakers



4.1. Introduction

4.2. Most active in hematology partnering

4.3. List of most active dealmakers in hematology

4.4. Top hematology deals by value



Chapter 5 – Hematology contract document directory



5.1. Introduction

5.2. Hematology partnering deals where contract document available



Chapter 6 – Hematology dealmaking by therapeutic target



6.1. Introduction

6.2. Deals by hematology therapeutic target



Deal directory



Deal directory – Hematology deals by company A-Z 2016 to 2023

Deal directory – Hematology deals by technology type 2016 to 2023



Deal type definitions



About Wildwood Ventures



Current Partnering

Current Agreements

Recent report titles from CurrentPartnering



Table of figures



Figure 1: Hematology partnering since 2016

Figure 2: Hematology partnering by deal type since 2016

Figure 3: Hematology partnering by industry sector since 2016

Figure 4: Hematology partnering by stage of development since 2016

Figure 5: Hematology partnering by technology type since 2016

Figure 6: Hematology partnering by indication since 2016

Figure 7: Hematology deals with a headline value

Figure 8: Hematology deals with upfront payment values

Figure 9: Hematology deals with milestone payment

Figure 10: Hematology deals with royalty rates

Figure 11: Active hematology dealmaking activity since 2016

Figure 12: Top hematology deals by value since 2016